Posted by Michael Wonder on 20 May 2017
CHMP recommends Veltassa for the treatment of hyperkalaemia in the EU
19 May 2017 - Opinion includes treatment of patients who develop hyperkalaemia while on RAAS inhibitors.
The CHMP of the EMA has recommended marketing authorisation for patiromer (brand name Veltassa) in all 31 EU/EAA countries for the control of elevated serum potassium levels (hyperkalaemia) in adult patients.
The recommendation specifies Veltassa for the treatment of hyperkalaemia in adult patients. This includes patients who develop hyperkalaemia while being treated with renin angiotensin aldosterone system (RAAS) inhibitor therapy. Nearly 100% of patients treated with Veltassa in the phase II-III clinical program were on RAASi at baseline.
